2021年，Guardant推出了Reveal，一种针对肿瘤未知分析的分子残留疾病（MRD）检测。2022年，该公司推出了Shield的实验室开发测试版本，这是用于结直肠癌 ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year ...

Guardant Health (GH) announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening ...

Guardant Health, Inc ... 2 The introduction of the Shield blood test is intended to be a significant step forward in improving screening participation, early detection and outcomes for the ...

to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational ...

to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational ...